Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1439222 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $35.01Day −2.72%Mkt cap $2.1B1Y −7.2%Off 52W high −23.9%Vol (1Y) 77.3%
Daily closing price, split-adjusted to the current basis; 3y shown of 3,271 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest11.1% of sh out |
| Days to cover6.4d |
| 13F net flow (QoQ)+5.17% |
| Top-10 13F concentration51.3% |
| Next report (est.)2026-10-28 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$66.0M |
| Earnings (TTM)-$422.6M |
| ROE−30.2% |
| Net margin−764.0% |
| ROIC−29.0% |
| Sales growth 3Y56.0% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+28.6% |
| 1Y−7.2% |
| 3Y+32.0% |
| 5Y−29.8% |
| 10Y−22.6% |
| Since incept. (ann.)+0.9% |
Total return through 2026-07-29 · series begins 2013-07-24. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)77.3% |
| Ann. volatility (3Y)61.5% |
| Sharpe (1Y)0.40 |
| Sharpe (3Y)0.50 |
| Max drawdown (1Y)−50.9% |
| Max drawdown (3Y)−63.8% |
| Beta (3Y vs SPY)1.18 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 5.8M | $195M | 9.82% | +9.9% |
| FARALLON CAPITAL MANAGEMENT LLC | 5.7M | $192M | 9.70% | +10.2% |
| STATE STREET CORP | 3.4M | $114M | 5.74% | +8.3% |
| ARMISTICE CAPITAL, LLC | 2.7M | $92M | 4.64% | −10.5% |
| D. E. Shaw & Co., Inc. | 2.7M | $91M | 4.58% | +45.9% |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.6M | $89M | 4.49% | new |
| Lynx1 Capital Management LP | 2.6M | $88M | 4.46% | +3179.9% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2.6M | $88M | 4.46% | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. Institutional 13F holdings sum to 107.6% of shares outstanding. Readings above 100% reflect securities-lending double counting: shares on loan to short sellers are reported long by both the lending institution and the one that bought them. FINRA short interest of 6,974,194 shares (settlement 2026-04-30) accounts for the excess.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-04-29 | −$1.69 | — | $20.7M | +137.7% |
| 2025-12-31 | 2026-02-12 | — | — | $20.0M | +86.1% |
| 2025-09-30 | 2025-10-30 | −$1.78 | −111.0% | $12.9M | +43.7% |
| 2025-06-30 | 2025-07-31 | −$1.93 | — | $12.5M | +44.6% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-10-28 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Product 100%
product & service · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
